Theralase® presented interim Phase II data showing Ruvidar™’s strong safety and efficacy in treating BCG-unresponsive bladder cancer, with durable complete responses, no serious drug-related adverse events, and potential for regulatory approval in 2026.
Theralase® Discovers New Mechanism of Action of Lead Drug
Theralase® announces Ruvidar™ inhibits Deubiquitinating Enzymes (DUBs), a key factor in cancer and drug resistance. This dual action—blocking DUBs and inducing oxidative stress—makes Ruvidar™ a promising cancer therapy candidate.
Theralase® Releases 2024 Annual Financial Statements
Theralase® reported a slight revenue decline in 2024 but reduced net loss, advanced clinical trials for cancer and Parkinson’s treatments, showed promising results in HSV and lymphoma studies, and plans FDA resubmissions.
CORRECTING AND REPLACING: Theralase® Demonstrates Effective Treatment of Herpes
Theralase® validated University of Manitoba research showing Ruvidar™ is safe and effective against HSV-1. Topical treatment healed lesions in four days, supporting its potential as a herpes therapeutic and clinical candidate.
Theralase® Demonstrates Effective Treatment of Herpes
Theralase® validated Ruvidar™ as safe and effective against HSV-1 in mice, with complete lesion healing in four days, supporting its potential for clinical use and advancement toward human trials.
Theralase® Releases Latest Research on Inactivation of Herpes Simplex Viruses
Theralase® announced University of Manitoba research showing Ruvidar™ is more effective than acyclovir in inhibiting HSV-1 post-infection, even without light, and offers enhanced antiviral effects in combination therapy.
Theralase® Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Theralase®’s bladder cancer treatment data was selected for podium presentation at the 2025 AUA Annual Meeting. Interim results show strong safety and efficacy, supporting Ruvidar™ as a breakthrough therapy option.
Theralase® Launches Three New Clinical Study Sites in USA
V.TLT | December 9, 2024 Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®’s bladder cancer treatment TORONTO, ON / December 9, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites (“CSSs“) for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio). The Principal Investigators (“PIs“) for the Theralase® clinical study at the new CSSs are as follows: Associated Medical Professionals of NY – Ilija Aleksic, MD Dr. … Read More
Theralase® Launches New Clinical Study Site in Canada
V.TLT | December 5, 2024 St. Joseph’s Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®’s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / December 5, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched a new Clinical Study Site (“CSS“) for its bladder cancer clinical study; specifically, St. Joseph’s Healthcare Hamilton (Hamilton, Ontario, Canada). Theralase®’s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System (“TLC-3200“) is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) with or without resected … Read More
Theralase® Release’s 3Q2024 Financial Statements
TORONTO, ON / November 27, 2024 / Theralase® Technologies Inc. (“ Theralase® ” or the “ Company “) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company’s unaudited condensed consolidated interim financial statements for the nine-month period ended September 30, 2024. (“ Financial Statements “). Theralase® will be hosting a conference call on Wednesday December 4 th at 11:00 am ET , which will include a presentation of the financial and operational results for the nine-month period ended September 30, 2024. Questions are welcome. To ensure Theralase® has time to review and properly address them during the call, please send them in advance to mperraton@theralase.com . Zoom Meeting Link: https://us02web.zoom.us/j/84816819001 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom. An archived version will be available on … Read More